THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO
The prospectus and all other information related to the Rights Issue will be available on the Company's website, www.medivir.com/investors/rights-issue-2021 and www.abgsc.com.New financial information
The prospectus includes not previously published information about
Capitalization
[][]
MSEK As of
Current liabilities
Guaranteed -
Secured -
Not guaranteed/secured 36.9
Total current liabilities 36.9
Non-current liabilities
Guaranteed -
Secured -
Not guaranteed/secured 33.1
Total non-current liabilities (excluding 33.1
the current portion of current
liabilities)
Shareholders' equity
Share capital 188.5
Other contributions 420.4
Retained earnings including the -456.0
profit/loss of the period[1)]
Total shareholder's equity[2)] 153.0
[1)] As of
[2)] Based on retained earnings including the result of the period as of
Net indebtedness
The Company's net debt as of
[]
MSEK As of
(A) Cash -
(B) Cash equivalents[1)] 14.9
(C) Readily realizable securities 60.9
(D) Total liquidity (A)+(B)+(C) 75.8
(E) Current financial receivables 11.7
(F) Current bank loans -
(G) Current portion of non-current liabilities 5.3
(H) Other current liabilities 31.6
(I) Total current financial liabilities (F)+(G)+(H) 36.9
(J) Net current financial indebtedness (I)-(E)-(D) -50.6
(K) Non-current bank loans -
(L) Bonds issued -
(M) Other non-current loans 33.1
(N) Non-current financial indebtedness (K)+(L)+(M) 33.1
(O) Net financial indebtedness (J)+(N) -17.5
[1)] Refers to the balance of the Company's bank accounts.
Advisors
For additional information, please contact:
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
The information was submitted for publication, through the agency of the contact persons set out above, at 9.40 CET on
About
Collaborations and partnerships are important parts of
Important information
Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in
This press release is not a prospectus according to the definition in Regulation (EU) 2017/2019 ("the Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. A prospectus has been prepared by the Company and approved by the
This press release does not constitute an offer or solicitation to buy or subscribe for securities in
http://publish.ne.cision.com//Release/ViewReleaseHtml/DBF83130FD08783CE0C856B0705FC7D6
https://mb.cision.com/Main/652/3269477/1360301.pdf
(c) 2021 Cision. All rights reserved., source